

# THROMBOCYTOPENIA

- Rituximab-associated cytopenia is a **self-limited** and uncomplicated phenomenon, usually occurring a few hours post-rituximab infusion, reaching nadir within 1 day and resolving spontaneously within a few days.<sup>(1)</sup>
- In patients with severe cytopenia (platelets  $<50000/\text{mm}^3$  and/or leukocytes  $<1000/\text{mm}^3$ ), rituximab therapy should be interrupted until the appropriate investigations and treatments are completed.<sup>(2)</sup>

- 
- (1) Ram, Ron, Lilach Bonstein, Anat Gafer-Gvili, Isaac Ben-Bassat, Ofer Shpilberg, and Pia Raanani. 2009. "Rituximab-Associated Acute Thrombocytopenia: An under-Diagnosed Phenomenon." *American Journal of Hematology* 84 (4): 247–50.
  - (2) Pham, Thao, Bruno Fautrel, Jacques-Eric Gottenberg, Philippe Goupille, Eric Hachulla, Charles Masson, Jacques Morel, et al. 2008. "Rituximab (MabThera) Therapy and Safety Management. Clinical Tool Guide Developed by the Rheumatic Diseases & Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Société Française de Rhumatologie, SFR)." *Joint, Bone, Spine: Revue Du Rhumatisme* 75 (June): S2–99.

